½ÃÀ庸°í¼­
»óǰÄÚµå
1375206

À¯·´ÀÇ ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ±â¼ú ½ÃÀå ¿¹Ãø(-2028³â) - À¯Çü, ¸ð´Þ¸®Æ¼, ÃÖÁ¾ »ç¿ëÀÚº° Áö¿ªº° ºÐ¼®

Europe Bioprocess Technology Market Forecast to 2028 - Regional Analysis By Type, Modality, and End User

¹ßÇàÀÏ: | ¸®¼­Ä¡»ç: The Insight Partners | ÆäÀÌÁö Á¤º¸: ¿µ¹® 143 Pages | ¹è¼Û¾È³» : Áï½Ã¹è¼Û

    
    
    



¡Ø º» »óǰÀº ¿µ¹® ÀÚ·á·Î Çѱ۰ú ¿µ¹® ¸ñÂ÷¿¡ ºÒÀÏÄ¡ÇÏ´Â ³»¿ëÀÌ ÀÖÀ» °æ¿ì ¿µ¹®À» ¿ì¼±ÇÕ´Ï´Ù. Á¤È®ÇÑ °ËÅ並 À§ÇØ ¿µ¹® ¸ñÂ÷¸¦ Âü°íÇØÁֽñ⠹ٶø´Ï´Ù.

À¯·´ÀÇ ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ±â¼ú ½ÃÀåÀº 2023³â 122¾ï 9,088¸¸ ´Þ·¯¿¡¼­ 2028³â 265¾ï 8,836¸¸ ´Þ·¯·Î ¼ºÀåÇÒ °ÍÀ¸·Î ¿¹ÃøµË´Ï´Ù. 2023³âºÎÅÍ 2028³â±îÁöÀÇ CAGRÀº 16.7%·Î ÃßÁ¤µË´Ï´Ù.

÷´Ü ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ±â¼ú µµÀÔÀÌ À¯·´ÀÇ ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ±â¼ú ½ÃÀåÀ» °ßÀÎ

÷´Ü ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ±â¼úÀº ¿¬±¸ °³¹ß ¹× »ý»êÀÇ ±³·®¿ªÇÒÀ» ÇÕ´Ï´Ù. ¿©·¯ ±â¾÷µéÀÌ ±¤¹üÀ§ÇÑ ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ½Å±â¼úÀ» ½ÃÀå¿¡ µµÀÔÇϰí ÀÖ½À´Ï´Ù. 2020³â 12¿ù 4ÀÏ, IDBS(¹ÙÀÌ¿ÀÅ×Å©³î·ÎÁö ¹× Á¦¾à »ê¾÷¿ë ¼ÒÇÁÆ®¿þ¾î ÀÎÆ÷¸Åƽ½º ¼Ö·ç¼Ç Á¦°ø¾÷ü)´Â Polar Ãâ½Ã¸¦ ¹ßÇ¥Çß½À´Ï´Ù. Polar´Â ¹ÙÀÌ¿ÀÆÄ¸¶ ¿¬±¸¿¡¼­ ÀǾàǰ °³¹ß°ú »ý»êÀ» °£¼ÒÈ­Çϱâ À§ÇØ ¹ÙÀÌ¿ÀÆÄ¸Ó ¶óÀÌÇÁ»çÀÌŬ ¸Å´ÏÁö¸ÕÆ®(BPLM)¶ó´Â »õ·Î¿î Á¦Ç° Ä«Å×°í¸®¸¦ ¼³¸³ÇÕ´Ï´Ù. Polar´Â ½ÇÇè½Ç Á¤º¸ °ü¸® ½Ã½ºÅÛ(LIMS) ¹× ÀüÀÚ¿¬±¸³ëÆ®(ELN)(ELN)¿Í °°Àº ±âÁ¸ ¼ÒÇÁÆ®¿þ¾î ¼Ö·ç¼ÇÀ» ±«·ÓÈ÷´Â ¿öÅ© Ç÷οì, ÇÁ·Î¼¼½º ǰÁú, Çù¾÷ ¹× µ¥ÀÌÅÍ ºÐ¼®°ú °ü·ÃµÈ ¹®Á¦¸¦ ½Å¼ÓÇÏ°Ô ÇØ°áÇϱâ À§ÇØ ¼³°èµÇ°í ¹èÆ÷µË´Ï´Ù. ±× °á°ú ÀÎÀû ¿À·ù°¡ ÁÙ¾îµé¾î ÀüüÀûÀÎ Á¤È®µµ°¡ Çâ»óµË´Ï´Ù. ¼öÀÛ¾÷À¸·Î µ¥ÀÌÅÍ Ã³¸® ¹× Àü±â¸¦ ÁÙ¿© ÈÞ¸Õ ¿À·ù¸¦ ÁÙÀ̰í Àü¹ÝÀûÀÎ Á¤È®µµ¸¦ ³ôÀÏ ¼ö ÀÖ½À´Ï´Ù. ¶ÇÇÑ °Ë»ö ±â´ÉÀÌ Ç³ºÎÇϱ⠶§¹®¿¡ »ç¿ëÀÚ°¡ ã°íÀÚ Çϴ´ °ÍÀ» ½±°Ô ãÀ» ¼ö ÀÖÀ¸¸ç ¹«ÀǹÌÇÑ ³ë·ÂÀÇ Áߺ¹À» ¹æÁö ÇÒ ¼ö ÀÖ½À´Ï´Ù.

METTLER TOLEDOÀÇ Dynochem Biologics´Â ¸ðµç ±Ô¸ðÀÇ ¹ÙÀÌ¿À ÇÁ·Î¼¼½º¿¡¼­ ¾÷½ºÆ®¸² ¹× ´Ù¿î½ºÆ®¸² ´ÜÀ§ Ȱµ¿À» Áö¿øÇÏ´Â Àü¿ë ½Ã¹Ä·¹ÀÌ¼Ç ¼ÒÇÁÆ®¿þ¾îÀÔ´Ï´Ù. ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ¿£Áö´Ï¾î¿Í °úÇÐÀÚ´Â ÀÌ ¼ÒÇÁÆ®¿þ¾î¸¦ »ç¿ëÇÏ¿© ÀûÀýÇÑ °øÁ¤ ÀÛµ¿ ÆÄ¶ó¹ÌÅ͸¦ ¼±ÅÃÇÏ°í ½ºÄÉÀÏÀÇ µ¿µî¼ºÀ» È®¸³ÇÕ´Ï´Ù. À¯Æ¿¸®Æ¼Àº ÃÖ¼ÒÇÑÀÇ µ¥ÀÌÅÍ·Î Àåºñ ¼º´ÉÀ» ½Å¼ÓÇÏ°Ô Æò°¡ÇÒ ¼ö ÀÖ´Â ¹Ý¸é, º¸´Ù °­·ÂÇÑ ¸ðµ¨Àº ±âÁ¸ µ¥ÀÌÅÍ ½ºÆ®¸²À» ÇÁ·Î¼¼½º Ư¼ºÈ­¿¡ Ȱ¿ëÇÕ´Ï´Ù. Áö¿ø °¡´ÉÇÑ ¿ëµµ Àü¹® Áö½Ä, dzºÎÇÑ ±³À° ¸®¼Ò½º ¹× ÀÌ¹Ì ±¸ÃàµÈ ¸ðµ¨ ¶óÀ̺귯¸®¸¦ Ȱ¿ëÇÏ¿© Ãʱâ ÇÁ·ÎÁ§Æ®¸¦ ½Å¼ÓÇÏ°Ô ¿Ï·áÇÒ ¼ö ÀÖ½À´Ï´Ù. ÆéƼµå, mAbs, ¿¹¹æ Á¢Á¾, ¹ÙÀÌ·¯½º º¤ÅÍ´Â ¸¹Àº ¾ÖÇø®ÄÉÀ̼ÇÀÇ ¿¹ÀÔ´Ï´Ù.

¸ÓÅ©ÀÇ »õ·Î¿î BioContinuum Ç÷§ÆûÀº È¿À²¼º Çâ»ó, °øÀå ¿î¿µ °£¼ÒÈ­, ǰÁú ¹× Àϰü¼º Çâ»óÀ» ÅëÇØ ¹ÙÀÌ¿À Ä¡·áÁ¦ Á¦Á¶¸¦ Áøº¸½Ãŵ´Ï´Ù. ¶ÇÇÑ, ¸ÓÅ©ÀÇ Pellicon Single-Pass Tangential Flow FiltrationÀº Ä¡·á ´Ü¹éÁúÀÇ Á¤Á¦¿Í °ü·ÃµÈ ¾÷¹« °­È­¸¦ Áö¿øÇÕ´Ï´Ù. µû¶ó¼­, ´Ù¾çÇÑ »õ·Î¿î ½Ã´ëÀÇ ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ±â¼úÀÇ µµÀÔÀº ¿¹Ãø ±â°£ µ¿¾È ½ÃÀå ¼ºÀå¿¡ À¯¸®ÇÑ ±âȸ¸¦ Á¦°øÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

À¯·´ÀÇ ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ±â¼ú ½ÃÀå °³¿ä

µ¶ÀÏ ¹«¿ªÅõÀÚû¿¡ µû¸£¸é À¯·´Àº ¼¼°è 2À§ÀÇ ÀǾàǰ ¼öÃâ±¹ÀÌ¸ç ¼¼°èÀÇ ÀǾàǰ »ý»ê±¹ÀÇ »óÀ§¿¡ ·©Å©µÇ°í ÀÖ½À´Ï´Ù. ¸ÂÃãÇü ÀÇ·á¿¡ ´ëÇÑ ¼ö¿ä°¡ Áõ°¡ÇÔ¿¡ µû¶ó µ¶ÀÏÀº »õ·Î¿î ¹ÙÀÌ¿À ÀǾàǰÀÇ ÁÖ¿ä °ø±Þ±¹ Áß Çϳª°¡µÇ¾ú½À´Ï´Ù. »ý¹° Á¦Á¦´Â ³ôÀº Ä¡·á È¿°ú¸¦ ±â´ëÇÒ ¼ö Àֱ⠶§¹®¿¡ µ¶ÀÏ ÀǾàǰ ½ÃÀå¿¡¼­ »ó´çÇÑ Á¡À¯À²À» Â÷ÁöÇÕ´Ï´Ù. µ¶ÀÏ ¹«¿ªÅõÀÚÃѼº(GTAI) º¸°í¼­¿¡ µû¸£¸é 2015³âºÎÅÍ 2019³â±îÁö »ý¹°Á¦Á¦ ½ÃÀåÀº ¿¬Æò±Õ 11.6% ¼ºÀåÇß´Ù(ÀǾàǰ ½ÃÀå Àüü ¼ºÀå·üÀÇ 2¹è ÀÌ»ó). µ¶ÀÏÀÇ ¹ÙÀÌ¿À ÀǾàǰÀÇ ÃÑ ¸ÅÃâÀº 2019³â¿¡ 139¾ï 6,000¸¸ ´Þ·¯¿¡ ´ÞÇßÀ¸¸ç ÀǾàǰ ½ÃÀåÀÇ 4ºÐÀÇ 1 ÀÌ»ó¿¡ ÇØ´çÇÕ´Ï´Ù. µ¶ÀÏÀº À¯·´ÀÇ ÁÖ¿ä ÀǾàǰ ½ÃÀåÀ» º¸À¯Çϰí ÀÖÀ¸¸ç ¼¼°è 4À§ÀÔ´Ï´Ù. 2019³â µ¶ÀÏ Á¦¾à¾÷°è ¸ÅÃâÀº 2018³âºÎÅÍ 5.7% Áõ°¡ÇÏ¿© 510¾ï 1,000¸¸ ´Þ·¯(Á¦Á¶¾÷ü ÃâÇÏ °¡°Ý)¿¡ À̸£·¶½À´Ï´Ù. µ¶ÀÏ¿¡´Â 500°³ ÀÌ»óÀÇ Á¦¾à ȸ»ç°¡ ÀÖ½À´Ï´Ù. Áß¼Ò±â¾÷Àº °æÁ¦ ºÎ¹®ÀÇ Æ÷À帶Â÷·Î, ÀǾàǰ Á¦Á¶¾÷üÀÇ ¾à 90%´Â Á÷¿ø ¼ö 500¸í ¹Ì¸¸ÀÔ´Ï´Ù. ¹ÙÀÌ¿ÀÅ×Å©³î·ÎÁö°¡ Á¦¾àȸ»çÀÇ ½ÅÁ¦Ç°, ½Å°øÁ¤, ½ÅÁ¦¹ý, ½Å¼­ºñ½ºÀÇ °³¹ß ¹× ±âÁ¸ Á¦Ç°ÀÇ °³·®¿¡ µµ¿òÀ» Áֱ⠶§¹®¿¡ À¯·´ÀÇ ÀǾàǰ ½ÃÀå °³Ã´Àº ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ±â¼úÀÇ ÀÌ¿ëÀ» ÃËÁøÇÒ °ÍÀ¸·Î º¸ÀÔ´Ï´Ù.

À¯·´ÀÇ ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ±â¼ú ½ÃÀå ¼öÀÍ ¹× 2028³â±îÁöÀÇ ¿¹Ãø(±Ý¾×)

À¯·´ ¹ÙÀÌ¿À ÇÁ·Î¼¼½º ±â¼ú ½ÃÀåÀÇ ¼¼ºÐÈ­

À¯·´ÀÇ ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ±â¼ú ½ÃÀåÀº À¯Çü, ¾ç½Ä, ÃÖÁ¾ »ç¿ëÀÚ, ±¹°¡·Î ±¸ºÐµË´Ï´Ù.

À¯Çüº°·Î À¯·´ÀÇ ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ±â¼ú ½ÃÀåÀº ¼¼Æ÷ ¹è¾ç ¹èÁö ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º, Å©·Î¸¶Åä ±×·¡ÇÇ ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º, ¼Ò¸ðǰ ¹× ¾×¼¼¼­¸® µîÀ¸·Î ±¸ºÐµË´Ï´Ù. 2023³â ¼Ò¸ðǰ ¹× ¾×¼¼¼­¸® ºÐ¾ß´Â À¯·´ÀÇ ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ±â¼ú ½ÃÀå¿¡¼­ °¡Àå Å« Á¡À¯À²À» ±â·ÏÇß½À´Ï´Ù.

¾ç½Ä¿¡ µû¶ó À¯·´ÀÇ ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ±â¼ú ½ÃÀåÀº ´ÜÀÏ »ç¿ë°ú ´ÙÁß »ç¿ëÀ¸·Î À̺е˴ϴÙ. 2023³â À¯·´ÀÇ ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ±â¼ú ½ÃÀå¿¡¼­´Â ´ÜÀÏ »ç¿ë ºÐ¾ß°¡ ´õ Å« Á¡À¯À²À» ±â·ÏÇß½À´Ï´Ù.

ÃÖÁ¾ »ç¿ëÀÚ¸¦ ±â¹ÝÀ¸·Î À¯·´ÀÇ ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ±â¼ú ½ÃÀåÀº Çмú ¹× ÀÇ·á ±â°ü, ¹ÙÀÌ¿À Á¦¾à ȸ»ç, ¿¬±¸¼Ò ¹× ±âŸ·Î ±¸ºÐµË´Ï´Ù. 2023³â ¹ÙÀÌ¿À Á¦¾à ȸ»ç ºÎ¹®Àº À¯·´ÀÇ ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ±â¼ú ½ÃÀå¿¡¼­ °¡Àå Å« Á¡À¯À²À» ±â·ÏÇß½À´Ï´Ù.

±¹°¡º°·Î À¯·´ÀÇ ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ±â¼ú ½ÃÀåÀº ¿µ±¹, µ¶ÀÏ, ÇÁ¶û½º, ÀÌÅ»¸®¾Æ, ½ºÆäÀÎ ¹× ±âŸ À¯·´À¸·Î ±¸ºÐµË´Ï´Ù. 2023³â µ¶ÀÏ ºÎ¹®Àº À¯·´ÀÇ ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ±â¼ú ½ÃÀå¿¡¼­ °¡Àå Å« Á¡À¯À²À» ±â·ÏÇß½À´Ï´Ù.

BioPharma Dynamics Ltd, Corning Inc, Danaher Corp, Eppendorf SE, Lonza Group AG, Merck KGaA, Repligen Corp, Sartorius AG, STAMM Biotech ¹× Thermo Fisher Scientific Inc´Â À¯·´ÀÇ ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ±â¼ú ½ÃÀå¿¡¼­ »ç¾÷À» Àü°³Çϰí ÀÖ´Â ÁÖ¿ä ±â¾÷ÀÔ´Ï´Ù.

¸ñÂ÷

Á¦1Àå ¼­¹®

Á¦2Àå À¯·´ÀÇ ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ±â¼ú ½ÃÀå-¿äÁ¡

Á¦3Àå Á¶»ç ¹æ¹ý

  • Á¶»ç ¹üÀ§
  • 2Â÷ Á¶»ç
  • 1Â÷ Á¶»ç

Á¦4Àå À¯·´ÀÇ ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ±â¼ú ½ÃÀå-½ÃÀå »óȲ

  • °³°ü
  • À¯·´ PEST ºÐ¼®
  • Àü¹®°¡ÀÇ °ßÇØ

Á¦5Àå À¯·´ÀÇ ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ±â¼ú ½ÃÀå : ÁÖ¿ä ½ÃÀå ¿ªÇÐ

  • ½ÃÀå ¼ºÀå ÃËÁø¿äÀÎ
    • ½Å¾à µµÀÔÀ» À§ÇÑ ¿¬±¸°³¹ßºñ Áõ°¡
    • ¸¸¼º Áúȯ Áõ°¡
  • ½ÃÀå ¼ºÀå ¾ïÁ¦¿äÀÎ
    • ¾ö°ÝÇÑ ±ÔÁ¦ Á¤Ã¥
  • ½ÃÀå ±âȸ
    • ÷´Ü ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ±â¼ú µµÀÔ
  • ÇâÈÄÀÇ µ¿Çâ
    • ÀÚµ¿ ½Ç½Ã°£ ÇÃ·Î¿ì »çÀÌÅä¸ÞÆ®¸®(ARTFCM)ÀÇ µîÀå
  • ¿µÇ⠺м®

Á¦6Àå ¹ÙÀÌ¿À ÇÁ·Î¼¼½º ±â¼ú ½ÃÀå : À¯·´ ºÐ¼®

  • À¯·´ÀÇ ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ±â¼ú ½ÃÀåÀÇ ¼öÀÍ ¹× ¿¹Ãø ºÐ¼®

Á¦7Àå À¯·´ÀÇ ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ±â¼ú ½ÃÀå ºÐ¼® ¹× ¿¹Ãø(-2028³â) : À¯Çüº°

  • ¼­¹®
  • À¯·´ÀÇ ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ±â¼ú ½ÃÀå : À¯Çüº°(2022-2028³â)(%)
  • ¼¼Æ÷ ¹è¾ç ¹èÁö ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º
  • Å©·Î¸¶Åä±×·¡ÇÇ ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º
  • ¼Ò¸ðǰ ¹× ¾×¼¼¼­¸®
  • ±âŸ

Á¦8Àå À¯·´ÀÇ ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ±â¼ú ½ÃÀå ºÐ¼® ¹× ¿¹Ãø(-2028³â) : ¸ð´Þ¸®Æ¼º°

  • ¼­¹®
  • À¯·´ÀÇ ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ±â¼ú ½ÃÀå : ¸ð´Þ¸®Æ¼º°(2022-2028³â)(%)
  • ½Ì±Û À¯½º
  • º¹¼ö ¿ëµµ

Á¦9Àå À¯·´ÀÇ ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ±â¼ú ½ÃÀå : ¼öÀÍ ¹× ¿¹Ãø(-2028³â) : ÃÖÁ¾ »ç¿ëÀÚº°

  • ¼­¹®
  • À¯·´ÀÇ ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ±â¼ú ½ÃÀå : ÃÖÁ¾ »ç¿ëÀÚº°(2022-2028³â)(%)
  • Çмú ¹× ÀÇ·á±â°ü
  • ¹ÙÀÌ¿À ÀǾàǰ±â¾÷
  • ¿¬±¸±â°ü
  • ±âŸ

Á¦10Àå À¯·´ÀÇ ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ±â¼ú ½ÃÀå : ¼öÀÍ ¹× ¿¹Ãø(-2028³â) : ±¹°¡º° ºÐ¼®

  • À¯·´
    • µ¶ÀÏ
    • ¿µ±¹
    • ÇÁ¶û½º
    • ÀÌÅ»¸®¾Æ
    • ½ºÆäÀÎ
    • ±âŸ À¯·´

Á¦11Àå À¯·´ÀÇ ¹ÙÀÌ¿ÀÇÁ·Î¼¼½º ±â¼ú ½ÃÀå : ¾÷°è Á¤¼¼

  • ¼­¹®
  • À¯±âÀû ¼ºÀå Àü·«
  • °³¿ä
  • ¹«±âÀû ¼ºÀå Àü·«
  • °³¿ä

Á¦12Àå ±â¾÷ ÇÁ·ÎÆÄÀÏ

  • Merck KGaA
  • Sartorius AG
  • Thermo Fisher Scientific Inc
  • Corning Inc
  • Lonza Group AG
  • Eppendorf SE
  • Repligen Corp
  • Danaher Corp
  • BioPharma Dynamics Ltd

Á¦13Àå ºÎ·Ï

AJY 23.11.17

The Europe bioprocess technology market is expected to grow from US$ 12,290.88 million in 2023 to US$ 26,588.36 million by 2028. It is estimated to grow at a CAGR of 16.7% from 2023 to 2028.

Introducing Advanced Bioprocess Technologies Drives Europe Bioprocess Technology Market

Advanced bioprocess technologies bridge R&D with production. Several players are introducing a wide range of new bioprocessing technologies in the market. On December 4, 2020, IDBS (a provider of software informatics solutions for the biotech and pharmaceutical industries) announced the launch of Polar. Polar creates a new product category called BioPharma Lifecycle Management (BPLM) to streamline drug development and production in biopharma research. Polar is designed and deployed to rapidly solve challenges associated with workflow, process quality, collaboration, and data analysis that have plagued the existing software solutions, including laboratory information management system (LIMS) and electronic laboratory notebook (ELN). As a result, there will be less human errors and an improvement in overall accuracy. It will reduce manual data processing and transcription, leading to fewer human errors and enhanced overall accuracy. It also has extensive search features that make it easier for users to locate what they are searching for, preventing the need for pointless duplication of effort.

METTLER TOLEDO's Dynochem Biologics is a purpose-built simulation software that supports upstream and downstream unit activities in bioprocessing at any scale. Bioprocess engineers and scientists use the software to choose appropriate process operating parameters and establish scales equivalency. Utilities enable quick evaluation of equipment performance with minimal data, whereas more potent models leverage the existing data streams for process characterization. Initial projects can be completed quickly with the help of responsive application expertise, rich training resources, and a model library that is already built. Peptides, mAbs, vaccinations, and viral vectors are a few examples of the many applications.

Merck's new BioContinuum Platform advances biotherapeutic drug manufacturing through improved efficiency, simplified plant operations, and greater quality and consistency. In addition, Merck's Pellicon Single-Pass Tangential Flow Filtration aid in intensifying operations associated with the purification of therapeutic proteins. Thus, the introduction of various new-age bioprocess technologies is likely to provide lucrative opportunities for the market growth during the forecast period.

Europe Bioprocess Technology Market Overview

According to Germany Trade & Invest, the country is the second largest exporter of medicinal products and ranks among the top pharmaceutical producers across the world. Owing to the rising demand for personalized medicine, Germany has also evolved into one of the main suppliers of novel biopharmaceuticals. Biologics hold a considerable share of the pharmaceutical market in Germany due to their high therapeutic potential. According to a report by Germany Trade & Invest (GTAI) from 2015 to 2019, the biologics market grew by 11.6 % on average annually (more than twice the growth of the overall pharma market). The total revenue of biopharmaceuticals in Germany was US$ 13.96 billion in 2019, equivalent to more than a quarter of the pharmaceutical market. Germany has a major European pharmaceutical market and is the fourth largest across the world. In 2019, sales in the pharmaceutical industry in Germany increased by 5.7 %, from 2018, reaching US$ 51.01 billion (ex-manufacturer prices). More than 500 pharmaceutical companies are located in Germany. SMEs are the backbone of the economic sector, with around 90% of drug manufacturers having less than 500 employees. Thus, the growing pharmaceutical market in Europe will propel the use of bioprocess technology as biotechnology helps the pharmaceutical companies develop new products, processes, methods, and services and improve existing ones.

Europe Bioprocess Technology Market Revenue and Forecast to 2028 (US$ Million)

Europe Bioprocess Technology Market Segmentation

The Europe bioprocess technology market is segmented into type, modality, end user, and country.

Based on type, the Europe bioprocess technology market is segmented into cell culture media bioprocess, chromatography bioprocess, and consumables & accessories, and others. In 2023, the consumables & accessories segment registered the largest share in the Europe bioprocess technology market.

Based on modality, the Europe bioprocess technology market is bifurcated into single use and multiple use. In 2023, the single use segment registered a larger share in the Europe bioprocess technology market.

Based on end user, the Europe bioprocess technology market is segmented into academic & medical institutions, biopharmaceutical companies, research laboratories, and others. In 2023, the biopharmaceutical companies segment registered the largest share in the Europe bioprocess technology market.

Based on country, the Europe bioprocess technology market is segmented into the UK, Germany, France, Italy, Spain, and the Rest of Europe. In 2023, Germany segment registered a largest share in the Europe bioprocess technology market.

BioPharma Dynamics Ltd; Corning Inc; Danaher Corp; Eppendorf SE; Lonza Group AG; Merck KGaA; Repligen Corp; Sartorius AG; STAMM Biotech; and Thermo Fisher Scientific Inc are the leading companies operating in the Europe bioprocess technology market.

Reasons to Buy:

  • Save and reduce time carrying out entry-level research by identifying the growth, size, leading players, and segments in the Europe bioprocess technology market.
  • Highlights key business priorities in order to assist companies to realign their business strategies
  • The key findings and recommendations highlight crucial progressive industry trends in the Europe bioprocess technology market, thereby allowing players across the value chain to develop effective long-term strategies
  • Develop/modify business expansion plans by using substantial growth offering developed and emerging markets
  • Scrutinize in-depth Europe market trends and outlook coupled with the factors driving the bioprocess technology market, as well as those hindering it
  • Enhance the decision-making process by understanding the strategies that underpin commercial interest with respect to client products, segmentation, pricing, and distribution

Table Of Contents

1. Introduction

  • 1.1 Scope of the Study
  • 1.2 The Insight Partners Research Report Guidance
  • 1.3 Market Segmentation
    • 1.3.1 Europe Bioprocess Technology Market - by Type
    • 1.3.2 Europe Bioprocess Technology Market - by Modality
    • 1.3.3 Europe Bioprocess Technology Market - by End User
    • 1.3.4 Europe Bioprocess Technology Market - by Country

2. Europe Bioprocess Technology Market - Key Takeaways

3. Research Methodology

  • 3.1 Coverage
  • 3.2 Secondary Research
  • 3.3 Primary Research

4. Europe Bioprocess Technology Market - Market Landscape

  • 4.1 Overview
  • 4.2 Europe PEST Analysis
  • 4.3 Expert's Opinion

5. Europe Bioprocess Technology Market - Key Market Dynamics

  • 5.1 Market Drivers
    • 5.1.1 Growing R&D Spendings to Introduce New Drug Compounds
    • 5.1.2 Increasing Prevalence of Chronic Diseases
  • 5.2 Market Restraints
    • 5.2.1 Stringent Regulatory Policies
  • 5.3 Market Opportunities
    • 5.3.1 Introducing Advanced Bioprocess Technologies
  • 5.4 Future Trends
    • 5.4.1 Emergence of Automated Real?Time Flow Cytometry (ART?FCM)
  • 5.5 Impact Analysis

6. Bioprocess Technology Market - Europe Analysis

  • 6.1 Europe Bioprocess Technology Market Revenue Forecast and Analysis

7. Europe Bioprocess Technology Market - Revenue and Forecast to 2028 - by Type

  • 7.1 Overview
  • 7.2 Europe Bioprocess Technology Market Revenue Share, by Type 2022 & 2028 (%)
  • 7.3 Cell Culture Media Bioprocess
    • 7.3.1 Overview
    • 7.3.2 Cell Culture Media Bioprocess: Europe Bioprocess Technology Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.4 Chromatography Bioprocess
    • 7.4.1 Overview
    • 7.4.2 Chromatography Bioprocess: Europe Bioprocess Technology Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.5 Consumables & Accessories
    • 7.5.1 Overview
    • 7.5.2 Consumables & Accessories: Europe Bioprocess Technology Market - Revenue and Forecast to 2028 (US$ Million)
  • 7.6 Others
    • 7.6.1 Overview
    • 7.6.2 Others: Europe Bioprocess Technology Market - Revenue and Forecast to 2028 (US$ Million)

8. Europe Bioprocess Technology Market Analysis and Forecasts to 2028 - by Modality

  • 8.1 Overview
  • 8.2 Europe Bioprocess Technology Market, by Modality 2022 & 2028 (%)
  • 8.3 Single Use
    • 8.3.1 Overview
    • 8.3.2 Single Use: Europe Bioprocess Technology Market - Revenue and Forecast to 2028 (US$ Million)
  • 8.4 Multiple Use
    • 8.4.1 Overview
    • 8.4.2 Multiple Use: Europe Bioprocess Technology Market - Revenue and Forecast to 2028 (US$ Million)

9. Europe Bioprocess Technology Market - Revenue and Forecast to 2028 - by End User

  • 9.1 Overview
  • 9.2 Europe Bioprocess Technology Market Revenue Share, by End User 2022 & 2028 (%)
  • 9.3 Academic & Medical Institutions
    • 9.3.1 Overview
    • 9.3.2 Academic & Medical Institutions: Europe Bioprocess Technology Market - Revenue and Forecast to 2028(US$ Million)
  • 9.4 Biopharmaceutical Companies
    • 9.4.1 Overview
    • 9.4.2 Biopharmaceutical Companies: Europe Bioprocess Technology Market - Revenue and Forecast to 2028 (US$ Million)
  • 9.5 Research Laboratories
    • 9.5.1 Overview
    • 9.5.2 Research Laboratories: Europe Bioprocess Technology Market - Revenue and Forecast to 2028 (US$ Million)
  • 9.6 Others
    • 9.6.1 Overview
    • 9.6.2 Others: Europe Bioprocess Technology Market - Revenue and Forecast to 2028 (US$ Million)

10. Europe Bioprocess Technology Market - Revenue and Forecast to 2028 - Country Analysis

  • 10.1 Overview
    • 10.1.1 Europe: Bioprocess Technology Market, by Country, 2022 & 2028 (%)
      • 10.1.1.1 Germany: Bioprocess Technology Market - Revenue and Forecast to 2028 (US$ Million)
        • 10.1.1.1.1 Overview
        • 10.1.1.1.2 Germany: Bioprocess Technology Market - Revenue and Forecast to 2028 (US$ Million)
        • 10.1.1.1.3 Germany: Bioprocess Technology Market, by Type, 2019-2028 (US$ Million)
        • 10.1.1.1.4 Germany: Bioprocess Technology Market, by Modality, 2019-2028 (US$ Million)
        • 10.1.1.1.5 Germany: Bioprocess Technology Market, by End User, 2019-2028 (US$ Million)
      • 10.1.1.2 UK: Bioprocess Technology Market - Revenue and Forecast to 2028 (US$ Million)
        • 10.1.1.2.1 Overview
        • 10.1.1.2.2 UK: Bioprocess Technology Market - Revenue and Forecast to 2028 (US$ Million)
        • 10.1.1.2.3 UK: Bioprocess Technology Market, by Type, 2019-2028 (US$ Million)
        • 10.1.1.2.4 UK: Bioprocess Technology Market, by Modality, 2019-2028 (US$ Million)
        • 10.1.1.2.5 UK: Bioprocess Technology Market, by End User, 2019-2028 (US$ Million)
      • 10.1.1.3 France: Bioprocess Technology Market - Revenue and Forecast to 2028 (US$ Million)
        • 10.1.1.3.1 Overview
        • 10.1.1.3.2 France: Bioprocess Technology Market - Revenue and Forecast to 2028 (US$ Million)
        • 10.1.1.3.3 France: Bioprocess Technology Market, by Type, 2019-2028 (US$ Million)
        • 10.1.1.3.4 France: Bioprocess Technology Market, by Modality, 2019-2028 (US$ Million)
        • 10.1.1.3.5 France: Bioprocess Technology Market, by End User, 2019-2028 (US$ Million)
      • 10.1.1.4 Italy: Bioprocess Technology Market - Revenue and Forecast to 2028 (US$ Million)
        • 10.1.1.4.1 Overview
        • 10.1.1.4.2 Italy: Bioprocess Technology Market - Revenue and Forecast to 2028 (US$ Million)
        • 10.1.1.4.3 Italy: Bioprocess Technology Market, by Type, 2019-2028 (US$ Million)
        • 10.1.1.4.4 Italy: Bioprocess Technology Market, by Modality, 2019-2028 (US$ Million)
        • 10.1.1.4.5 Italy: Bioprocess Technology Market, by End User, 2019-2028 (US$ Million)
      • 10.1.1.5 Spain: Bioprocess Technology Market - Revenue and Forecast to 2028 (US$ Million)
        • 10.1.1.5.1 Overview
        • 10.1.1.5.2 Spain: Bioprocess Technology Market - Revenue and Forecast to 2028 (US$ Million)
        • 10.1.1.5.3 Spain: Bioprocess Technology Market, by Type, 2019-2028 (US$ Million)
        • 10.1.1.5.4 Spain: Bioprocess Technology Market, by Modality, 2019-2028 (US$ Million)
        • 10.1.1.5.5 Spain: Bioprocess Technology Market, by End User, 2019-2028 (US$ Million)
      • 10.1.1.6 Rest of Europe: Bioprocess Technology Market - Revenue and Forecast to 2028 (US$ Million)
        • 10.1.1.6.1 Overview
        • 10.1.1.6.2 Rest of Europe: Bioprocess Technology Market - Revenue and Forecast to 2028 (US$ Million)
        • 10.1.1.6.3 Rest of Europe: Bioprocess Technology Market, by Type, 2019-2028 (US$ Million)
        • 10.1.1.6.4 Rest of Europe: Bioprocess Technology Market, by Modality, 2019-2028 (US$ Million)
        • 10.1.1.6.5 Rest of Europe: Bioprocess Technology Market, by End User, 2019-2028 (US$ Million)

11. Europe Bioprocess Technology Market - Industry Landscape

  • 11.1 Overview
  • 11.2 Organic Growth Strategies
    • 11.2.1 Overview
  • 11.3 Inorganic Growth Strategies
    • 11.3.1 Overview

12. Company Profiles

  • 12.1 Merck KGaA
    • 12.1.1 Key Facts
    • 12.1.2 Business Description
    • 12.1.3 Products and Services
    • 12.1.4 Financial Overview
    • 12.1.5 SWOT Analysis
    • 12.1.6 Key Developments
  • 12.2 Sartorius AG
    • 12.2.1 Key Facts
    • 12.2.2 Business Description
    • 12.2.3 Products and Services
    • 12.2.4 Financial Overview
    • 12.2.5 SWOT Analysis
    • 12.2.6 Key Developments
  • 12.3 Thermo Fisher Scientific Inc
    • 12.3.1 Key Facts
    • 12.3.2 Business Description
    • 12.3.3 Products and Services
    • 12.3.4 Financial Overview
    • 12.3.5 SWOT Analysis
    • 12.3.6 Key Developments
  • 12.4 Corning Inc
    • 12.4.1 Key Facts
    • 12.4.2 Business Description
    • 12.4.3 Products and Services
    • 12.4.4 Financial Overview
    • 12.4.5 SWOT Analysis
    • 12.4.6 Key Developments
  • 12.5 Lonza Group AG
    • 12.5.1 Key Facts
    • 12.5.2 Business Description
    • 12.5.3 Products and Services
    • 12.5.4 Financial Overview
    • 12.5.5 SWOT Analysis
    • 12.5.6 Key Developments
  • 12.6 Eppendorf SE
    • 12.6.1 Key Facts
    • 12.6.2 Business Description
    • 12.6.3 Products and Services
    • 12.6.4 Financial Overview
    • 12.6.5 SWOT Analysis
    • 12.6.6 Key Developments
  • 12.7 Repligen Corp
    • 12.7.1 Key Facts
    • 12.7.2 Business Description
    • 12.7.3 Products and Services
    • 12.7.4 Financial Overview
    • 12.7.5 SWOT Analysis
    • 12.7.6 Key Developments
  • 12.8 Danaher Corp
    • 12.8.1 Key Facts
    • 12.8.2 Business Description
    • 12.8.3 Products and Services
    • 12.8.4 Financial Overview
    • 12.8.5 SWOT Analysis
    • 12.8.6 Key Developments
  • 12.9 BioPharma Dynamics Ltd
    • 12.9.1 Key Facts
    • 12.9.2 Business Description
    • 12.9.3 Products and Services
    • 12.9.4 Financial Overview
    • 12.9.5 SWOT Analysis
    • 12.9.6 Key Developments

13. Appendix

  • 13.1 About The Insight Partners
  • 13.2 Glossary of Terms
ºñ±³¸®½ºÆ®
0 °ÇÀÇ »óǰÀ» ¼±Åà Áß
»óǰ ºñ±³Çϱâ
Àüü»èÁ¦